Clinical Trials | 01 June 2026
Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
This marks one of the most closely watched oncology readouts at this year’s medical congress
This marks one of the most closely watched oncology readouts at this year’s medical congress
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
A one-shot gene-editing cholesterol therapy could soon be a reality
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
NEJM study shows strong protection across strains
Subscribe To Our Newsletter & Stay Updated
